Article Figures & Data
Figures
- FIGURE 2.
Mean 18F-FLT SUV changes for patients as function of time for patients with more or less than 12-mo survival. Initial drop of SUV is universally observed.
- FIGURE 3.
OS Kaplan–Meier curves separated by 18F -FLT PET based on baseline to 2 wk (A), baseline to 6 wk (B), and 2–6 wk (C) response criteria.
- FIGURE 4.
PFS Kaplan–Meier curves separated by 18F-FLT PET based on baseline to 2 wk (A), baseline to 6 wk (B), and 2–6 wk (C) response criteria.
Tables
Characteristic n Sex Female 12 Male 18 Tumor grade Grade III 6 Grade IV 24 KPS 70–80 13 90–100 17 No. of recurrences 1–2 24 3–4 5 5 1 Dexamethasone treatment Absence 12 Presence 18 Median age of patients was 58 y, and age range was 26–78 y.
SUV Response (6 wk) Patient no. Sex Age (y) Diagnosis Baseline 2 wk after treatment start 6 wk after treatment start Change at 2 wk Change at 6 wk Change between 2 and 6 wk 18F-FLT PET MRI* PFS (mo) OS (mo) 1 F 38 AA 0.74 0.59 0.78 −20% +5% +32% No SD 5.0 8.5 2 M 78 GBM 1.57 2.28 ND 45% NA NA No PD 0.5 0.8 3 M 64 GBM 0.88 0.68 0.63 −23% −28% −7% Yes PR 2.2 7.6 4 F 45 GBM 0.74 0.82 1.67 +11% +126% +104% No SD 1.7 11.3 5 M 37 GBM 1.56 1.30 1.39 −17% +11% +7% No SD 3.8 4.0 6 M 65 AA 0.83 0.44 0.56 −47% −33% +27% Yes † 3.6 4.6 7 M 65 AMG 0.64 0.50 ND −22% NA NA No PD 0.7 2.6 8 F 61 GBM 1.69 1.16 1.15 −31% −32% −1% Yes‡ SD‡ 4.5 13.1 9 M 69 GBM 0.45 0.45 0.39 0% −13% −13% No‡ PR‡ 2.8 2.8 10 M 26 GBM 0.75 0.74 1.08 −1% +44% +46% No SD 3.2 11.5 11 F 65 GBM 0.69 0.60 1.20 −13% +74% +100% No SD 2.5 3.5 12 F 35 GBM 0.72 0.33 0.35 −54% −51% +6% Yes‡ PD‡ 2.1 10.4 13 F 62 GBM 0.59 0.37 0.39 −37% −34% +5% Yes PR 8.9 23.2 14 M 28 AA 0.81 0.46 0.62 −43% −23% +35% No PD 1.5 7.7 15 F 68 GBM 1.34 1.04 ND −22% NA NA No PD 1.1 1.6 16 F 47 GBM 2.35 1.42 1.33 −40% −43% −6% Yes‡ SD‡ 5.6 12.7 17 F 54 GBM 1.22 0.61 0.65 −50% −47% +7% Yes PR 7.3 12.1 18 M 58 GBM 4.79 1.78 5.24 −63% +9% +194% No SD 1.6 3.2 19 M 46 GBM 1.81 0.82 0.62 −55% −66% −24% Yes‡ SD‡ 2.4 11.2 20‡ M 50 AA 0.22 0.22 1.22 −79% −56%¶ +109% No¶ SD 0.9 1.9 21 M 70 GBM 0.91 0.63 0.42 −31% −54% −33% Yes PR 6.7 12.9 22 M 66 GBM 0.94 0.62 0.51 −34% −46% −18% Yes‡ SD‡ 11.1 12.3 23 M 47 GBM 0.38 0.19 0.19 −50% −50% 0% Yes CR 18.2 34.3 24 F 58 GBM 1.01 0.89 1.60 −12% +58% +80% No SD 1.3 5.5 25 M 76 GBM 1.36 0.25 0.22 −82% −84% −12% Yes CR 24.0 32.0 26 M 68 GBM 2.02 1.74 1.26 −14% −38% −28% Yes PR 6.9 10.1 27 F 37 GBM 1.32 0.95 0.89 −28% −33% −6% Yes PR 10.6 14.6 28 M 37 AA 0.86 0.51 0.88 −41% +2% +73% No PD 1.9 9.5 29 M 57 GBM 0.66 0.48 0.35 −27% −47% −27% Yes‡ SD‡ 4.2 19.5 30 F 41 GBM 1.99 1.06 1.01 −47% −49% −5% Yes‡ PD‡ 1.4 12.0 ↵* This being MRI evaluation at 6 wk, no 4-wk sustained response requirement for responders based on RANO (14) was taken into consideration for this evaluation.
↵† Follow-up MRI not available for evaluation.
↵‡ Mismatch between MRI and PET response assessment.
↵¶ Patient developed second lesion after 2 wk.
AA= anaplastic astrocytoma; SD = stable disease; GBM = glioblastoma multiforme; ND = not done; NA = not applicable; AMG = anaplastic mixed glioma.
OS PFS Univariate Multivariate Univariate Multivariate Predictive factor P HR P HR P HR P HR Age 0.939 0.325 No. of recurrences 0.001 2.243 0.645 0.001 2.044 0.267 Baseline KPS 0.06 0.915 Dexamethasone treatment 0.176 0.731 Tumor size change by MRI 0.016 3.220 0.382 0.003 4.151 0.054 Lack of 18F-FLT reduction, 0−2 wk 0.001 5.416 0.795 0.024 2.590 0.264 Lack of 18F-FLT reduction, 0–6 wk <0.001 7.869 <0.001 10.051 0.001 5.225 0.001 5.636 Lack of 18F-FLT increase, 2–6 wk 0.001 5.739 0.674 0.009 3.197 0.833
Jump to section
Related Articles
Cited By...
- Influence of Bevacizumab on Blood-Brain Barrier Permeability and O-(2-18F-Fluoroethyl)-L-Tyrosine Uptake in Rat Gliomas
- Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma
- Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- Comparison of the Amino Acid Tracers 18F-FET and 18F-DOPA in High-Grade Glioma Patients
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
- The Translocator Protein Radioligand 18F-DPA-714 Monitors Antitumor Effect of Erufosine in a Rat 9L Intracranial Glioma Model
- PET Imaging of Proliferation with Pyrimidines
- [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941
- 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome
- 3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients